ClinicalTrials.gg
TerminatedNCT04329949RELIANTUpdated Nov 18, 2023Results posted

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

A Phase 3 interventional study of Relacorilant, 100 mg and 25 mg and Nab-paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma, sponsored by Corcept Therapeutics. Terminated at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Corcept Therapeutics · Phase 3, Interventional, and Treatment

Why this study was terminated
The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 300 open to participants now, 474 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
697th of 1,574
43 · median 37
Started
2020
with 82 others
Phase 3
80 of 1,851
14 open now
Registered
1,328th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 697th largest by enrollment of the 1,574 interventional ones that give a count, is one of 83 that started in 2020, is one of 80 in phase 3, and was the 1,328th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

300 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

295 more — sign in →

All 300 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to blinded independent central review.

Read the detailed description

Relacorilant is a small-molecule antagonist of the glucocorticoid receptor (GR). The goals of this study are to evaluate the efficacy, safety, and pharmacokinetics (PK) of relacorilant in combination with nab-paclitaxel in the treatment of metastatic pancreatic ductal adenocarcinoma.

Eligible patients are those with mPDAC who have received at least 2 prior lines of therapy for pancreatic ductal adenocarcinoma in any setting, including at least 1 prior gemcitabine-based therapy and at least 1 prior fluoropyrimidine-based therapy.

Patients will receive treatment until progressive disease (PD) (per RECIST v1.1) as determined by the Investigator, experiencing unmanageable toxicity, or until other treatment discontinuation criteria are met. All patients will be followed for documentation of disease progression and survival information (i.e., date and cause of death) and subsequent treatment.

03

Conditions studied

  • Metastatic Pancreatic Ductal Adenocarcinoma

Keywords

  • Pancreatic Cancer
  • mPDAC
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Glucocorticoid Receptor
  • Nab-paclitaxel
  • GR Antagonist
  • Relacorilant
  • Abraxane
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Patients must have the following:

confirmed PDAC with disease

Received at least 2 for PDAC in any setting, including at least 1 prior gemcitabine-based therapy and at least 1 prior fluoropyrimidine-based therapy

Received no more than 4 prior lines of cytotoxic or myelosuppressive therapy for PDAC

A at baseline (within 21 days prior to the first dose of relacorilant) per v1.1, as assessed by the Investigator

Willingness to provide blood samples and tumor tissue (primary or metastatic) for research purposes

performance status (KPS) score of ≥70

Adequate gastrointestinal absorption. If the patient has undergone gastric bypass surgery and/or surgery of gastrointestinal or hepatobiliary tract, the patient must demonstrate adequate absorption as evidenced by albumin ≥3.0 g/dL, controlled pancreatic insufficiency (if present), and lack of evidence of malabsorption

Adequate organ and marrow function (determined through blood and urine tests)

Exclusion Criteria - Patients must not have the following:

Pancreatic neuroendocrine tumors, lymphoma of the pancreas, acinar pancreatic cancer, or ampullary cancer

Known untreated parenchymal or have uncontrolled central nervous system metastases. Patients must not require and must be neurologically stable without corticosteroids for a minimum of 3 weeks prior to Cycle 1 Day 1

toxicity from prior systemic cytotoxic therapies or radiotherapy that in the opinion of the Investigator has not resolved to Grade 1 or less prior to enrollment, including peripheral neuropathy that is ongoing and greater than Grade 1 in severity, according to National Cancer Institute (NCI-CTCAE) v5.0

History of or severe reaction to either relacorilant or nab-paclitaxel, or to similar classes of either drug

Taken the following medications prior to enrollment:

  1. An product, cytotoxic chemotherapy, or targeted agent within 14 days
  2. Radiotherapy within 21 days
  3. Palliative radiotherapy within 1 week of Cycle 1 Day 1, or if toxicities from radiotherapy are Grade 2 severity or higher or have not recovered to baseline
  4. Systemic or prescription-strength topical corticosteroids for the purposes of treating a chronic nononcologic indication within 21 days.

Requirement for treatment with chronic or frequently used oral or inhaled corticosteroids for medical conditions or illnesses (e.g., rheumatoid arthritis, asthma, or after organ transplantation)

Taking a concomitant medication that is a strong (cytochrome P450 3A) or CYP2C8 inhibitor or inducer, or a substrate of CYP3A or CYP2C8 and has a narrow therapeutic window

Concurrent treatment with mifepristone or other GR antagonists

Any clinically significant uncontrolled condition(s) or any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities or impair study participation or cooperation

Any major surgery within 21 days prior to enrollment

Endoscopic retrograde cholangiopancreatography with persistence of any of the following:

  1. ≥1.5 × (Upper Limit of Normal)
  2. Amylase >2 × ULN and abdominal pain or amylase >3 × ULN (with or without symptoms)
  3. Fever or signs of infection
  4. Decreasing or signs of blood loss.

A history of (HIV) or current chronic/active infection with virus (HCV) or virus (HBV). (Patients with chronic or active hepatitis B as diagnosed by serologic tests are excluded from the study. In equivocal cases, hepatitis B or C polymerase chain reaction results may be performed and must be negative for enrollment.)

A rapid decline in KPS score or serum albumin (≥20%), or have progressive pain symptoms indicative of rapid clinical deterioration, in the opinion of the Investigator, prior to enrollment. These patients will become ineligible if rapid decline is observed during the screening period.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Relacorilant with nab-paclitaxel

    Patients will be treated with relacorilant, administered orally, once daily in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.

    Drug: Relacorilant, 100 mg and 25 mg · Drug: Nab-paclitaxel

Interventions

  • DrugRelacorilant, 100 mg and 25 mg

    Drug page: Relacorilant

    Relacorilant is supplied as capsules for oral dosing.

    Also known as: CORT125134

  • Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.

    Also known as: Abraxane

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)

    Percentage of patients with measurable disease at baseline who achieved confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by Blinded Independent Central Review (BICR). Tumor assessment consisted of computerized tomography (CT) scan or, with Sponsor approval, magnetic resonance imaging (MRI). CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the diameters (SOD) of target lesions.

    Time frame: Baseline and up to 32 weeks

Secondary outcomes

  1. Objective Response Rate (ORR) Per Investigator Assessment

    Percentage of patients with measurable disease at baseline who achieved confirmed CR or PR per RECIST v1.1, as assessed by the Investigator. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions.

    Time frame: Baseline and up to 48 weeks

  2. Best Overall Response (BOR)

    To evaluate the best overall response of CR, PR, stable disease (SD), or PD per RECIST v1.1. as assessed by BICR. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

    Time frame: Baseline and up to 32 weeks

  3. Duration of Response (DOR)

    To evaluate the duration of response as the time of objective response (CR or PR) to the time of disease progression or death, per RECIST v1.1 as assessed by BICR and the Investigator. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions. PD was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

    Time frame: Time of response up to 32 weeks

  4. Disease Control Rate (DCR)

    To evaluate patients disease control rate of CR, PR, or SD at 18 weeks, per RECIST v1.1 as assessed by the Investigator. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Enrollment through 18 weeks

  5. Progression-Free Survival (PFS)

    To evaluate PFS as median time to disease progression per RECIST v1.1, or death, as assessed by BICR. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. Disease progression was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

    Time frame: Baseline and up to 31 weeks.

  6. Overall Survival (OS)

    To evaluate OS as median time to death by any cause.

    Time frame: Baseline and up to 70 weeks

  7. Progression-Free Survival (PFS)

    To evaluate PFS as the percentage of patients who are progression-free at 3, 6, and 12 months per RECIST v1.1, as assessed by BICR. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. Disease progression was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

    Time frame: Enrollment through 3 months, 6 months, and 12 months

  8. Overall Survival (OS)

    To evaluate OS as the percentage of patients surviving at 3, 6, and 12, months.

    Time frame: Enrollment through 3 months, 6 months, and 12 months

  9. Cancer Antigen (CA)19-9

    To assess cancer antigen 19-9 (CA19-9) response at 8 and 16 weeks in patients who have elevated CA19-9 at baseline. Response was defined as ≥50% reduction in CA19-9.

    Time frame: Enrollment through 8 weeks and 16 weeks

  10. Tumor Response Per European Organization for Research and Treatment of Cancer (EORTC) Criteria

    To assess tumor response based on changes in fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at 6 weeks per the EORTC criteria, as assessed by BICR.

    Time frame: Enrollment through 6 weeks

  11. Time to Progression (TTP)

    To evaluate TTP as median time to disease progression per RECIST v1.1, as assessed by the Investigator. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. Disease progression was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

    Time frame: Baseline and up to 32 weeks

07

Results

Posted Nov 18, 2023
Limitations and caveats
The independent data monitoring committee found no safety issues, however the observed response rate did not meet the predefined threshold for continuing the study. The study was terminated by the Sponsor.

Participant flow

Patients were recruited at 18 study sites in the United States.

Participant flow — Overall Study
MilestoneRelacorilant With Nab-paclitaxel
Started43
Completed0
Not completed43
Withdrew: Death36
Withdrew: Withdrawal by subject4
Withdrew: Termination of study by sponsor3

Outcome measures

PrimaryObjective Response Rate (ORR) Per Blinded Independent Central Review (BICR)

Percentage of patients with measurable disease at baseline who achieved confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by Blinded Independent Central Review (BICR). Tumor assessment consisted of computerized tomography (CT) scan or, with Sponsor approval, magnetic resonance imaging (MRI). CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the sum of the diameters (SOD) of target lesions.

Time frame:
Baseline and up to 32 weeks
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)
ParticipantsRelacorilant With Nab-paclitaxel
Complete response0
Partial response0
No response43
SecondaryObjective Response Rate (ORR) Per Investigator Assessment

Percentage of patients with measurable disease at baseline who achieved confirmed CR or PR per RECIST v1.1, as assessed by the Investigator. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions.

Time frame:
Baseline and up to 48 weeks
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) Per Investigator Assessment
ParticipantsRelacorilant With Nab-paclitaxel
Complete response0
Partial response0
No response43
SecondaryBest Overall Response (BOR)

To evaluate the best overall response of CR, PR, stable disease (SD), or PD per RECIST v1.1. as assessed by BICR. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. PD was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

Time frame:
Baseline and up to 32 weeks
Reported as:
Count of participants · Participants
Best Overall Response (BOR)
ParticipantsRelacorilant With Nab-paclitaxel
Complete response0
Partial response0
Stable disease20
Progressive disease10
Non-evaluable1
SecondaryDuration of Response (DOR)

To evaluate the duration of response as the time of objective response (CR or PR) to the time of disease progression or death, per RECIST v1.1 as assessed by BICR and the Investigator. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions. PD was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

Time frame:
Time of response up to 32 weeks

No measurements were reported for this outcome.

SecondaryDisease Control Rate (DCR)

To evaluate patients disease control rate of CR, PR, or SD at 18 weeks, per RECIST v1.1 as assessed by the Investigator. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. CR was defined as disappearance of all target lesions; any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Enrollment through 18 weeks
Reported as:
Count of participants · Participants
Disease Control Rate (DCR)
ParticipantsRelacorilant With Nab-paclitaxel
Disease Control Rate (DCR)5
SecondaryProgression-Free Survival (PFS)

To evaluate PFS as median time to disease progression per RECIST v1.1, or death, as assessed by BICR. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. Disease progression was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

Time frame:
Baseline and up to 31 weeks.
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsRelacorilant With Nab-paclitaxel
Progression-Free Survival (PFS)2.4 (1.4 to 4.2)
SecondaryOverall Survival (OS)

To evaluate OS as median time to death by any cause.

Time frame:
Baseline and up to 70 weeks
Reported as:
Median · Months
Overall Survival (OS)
MonthsRelacorilant With Nab-paclitaxel
Overall Survival (OS)3.9 (2.8 to 4.9)
SecondaryProgression-Free Survival (PFS)

To evaluate PFS as the percentage of patients who are progression-free at 3, 6, and 12 months per RECIST v1.1, as assessed by BICR. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. Disease progression was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

Time frame:
Enrollment through 3 months, 6 months, and 12 months
Reported as:
Number · Percentage of participants
Progression-Free Survival (PFS)
Percentage of participantsRelacorilant With Nab-paclitaxel
3 months44.77 (28.97 to 59.38)
6 months8.00 (1.57 to 21.50)
12 monthsNA (NA to NA)
SecondaryOverall Survival (OS)

To evaluate OS as the percentage of patients surviving at 3, 6, and 12, months.

Time frame:
Enrollment through 3 months, 6 months, and 12 months
Reported as:
Number · Percentage of participants
Overall Survival (OS)
Percentage of participantsRelacorilant With Nab-paclitaxel
3 months64.12 (47.65 to 76.61)
6 months21.55 (10.23 to 35.58)
12 months10.77 (3.44 to 22.91)
SecondaryCancer Antigen (CA)19-9

To assess cancer antigen 19-9 (CA19-9) response at 8 and 16 weeks in patients who have elevated CA19-9 at baseline. Response was defined as ≥50% reduction in CA19-9.

Time frame:
Enrollment through 8 weeks and 16 weeks
Reported as:
Count of participants · Participants
Cancer Antigen (CA)19-9
ParticipantsRelacorilant With Nab-paclitaxel
8 weeks5
16 weeks3
SecondaryTumor Response Per European Organization for Research and Treatment of Cancer (EORTC) Criteria

To assess tumor response based on changes in fluorodeoxyglucose-positron emission tomography (FDG-PET) scan at 6 weeks per the EORTC criteria, as assessed by BICR.

Time frame:
Enrollment through 6 weeks
Reported as:
Count of participants · Participants
Tumor Response Per European Organization for Research and Treatment of Cancer (EORTC) Criteria
ParticipantsRelacorilant With Nab-paclitaxel
Complete metabolic response0
Partial metabolic response6
Stable metabolic disease9
Progressive metabolic disease8
SecondaryTime to Progression (TTP)

To evaluate TTP as median time to disease progression per RECIST v1.1, as assessed by the Investigator. Tumor assessment consisted of CT scan or, with Sponsor approval, MRI. Disease progression was defined as ≥20% increase in the SOD of target lesions or the appearance of one or more new lesions.

Time frame:
Baseline and up to 32 weeks
Reported as:
Median · Months
Time to Progression (TTP)
MonthsRelacorilant With Nab-paclitaxel
Time to Progression (TTP)4.2 (1.6 to NA)

Adverse events

Collected over Up to 30 days after the last dose of study treatment (up to 73 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Relacorilant With Nab-paclitaxel36/43 (83.7%)23/43 (53.5%)43/43 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventRelacorilant With Nab-paclitaxel
Pulmonary embolismRespiratory, thoracic and mediastinal disorders6/43
Abdominal painGastrointestinal disorders3/43
SepsisInfections and infestations3/43
AscitesGastrointestinal disorders2/43
Obstruction gastricGastrointestinal disorders2/43
FatigueGeneral disorders2/43
AnaemiaBlood and lymphatic system disorders1/43
Febrile neutropeniaBlood and lymphatic system disorders1/43
PancytopeniaBlood and lymphatic system disorders1/43
Atrial FibrillationCardiac disorders1/43
Most frequent other events
Showing 10 of 47
Most frequent other events
EventRelacorilant With Nab-paclitaxel
FatigueGeneral disorders34/43
NauseaGastrointestinal disorders21/43
Decreased appetiteMetabolism and nutrition disorders17/43
VomitingGastrointestinal disorders14/43
AnaemiaBlood and lymphatic system disorders13/43
Neutrophil count decreasedInvestigations12/43
HypoalbuminaemiaMetabolism and nutrition disorders12/43
Back painMusculoskeletal and connective tissue disorders11/43
Abdominal painGastrointestinal disorders10/43
HypokalaemiaMetabolism and nutrition disorders10/43

Baseline characteristics

All enrolled patients

Age, Continuous
Age, Continuous(Years)Relacorilant With Nab-paclitaxel
Mean65.2 ± 8.14
Sex: Female, Male
Sex: Female, Male(Participants)Relacorilant With Nab-paclitaxel
Female19
Male24
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Relacorilant With Nab-paclitaxel
Hispanic or Latino3
Not Hispanic or Latino37
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Relacorilant With Nab-paclitaxel
American Indian or Alaska Native0
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American3
White35
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Relacorilant With Nab-paclitaxel
United States43
08

Study locations

18 sites
  • Site #038
    Scottsdale, Arizona 85258, United States
  • Site #171
    Duarte, California 91010, United States
  • Site #076
    Los Angeles, California 90095, United States
  • Site #032
    Aurora, Colorado 80045, United States
  • Site #009
    Atlanta, Georgia 30322, United States
  • Site #184
    Goshen, Indiana 46526, United States
  • Site #065
    Baltimore, Maryland 21231, United States
  • Site #058
    Detroit, Michigan 48201, United States
  • Site #185
    Omaha, Nebraska 68114, United States
  • Site #182
    Buffalo, New York 14263, United States
  • Site #044
    New York, New York 10016, United States
  • Site #222
    New York, New York 10016, United States
  • Site #077
    Columbus, Ohio 43210, United States
  • Site #186
    Toledo, Ohio 43614, United States
  • Site #172
    Pittsburgh, Pennsylvania 15232, United States
  • Site #175
    Knoxville, Tennessee 37920, United States
  • Site #176
    Nashville, Tennessee 37232, United States
  • Site #173
    Seattle, Washington 98195, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Aug 2021, 13 months.

Results were first posted in Nov 2023, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2020
First posted
Apr 1, 2020
StartActual
Jun 30, 2020
Primary completionActual
Aug 23, 2021
CompletionActual
Mar 25, 2022
Results first posted
Nov 18, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04329949
Responsible party
Sponsor
First posted
Apr 1, 2020
Start date
Jun 30, 2020
Primary completion
Aug 23, 2021
Completion
Mar 25, 2022
Results posted
Nov 18, 2023
Last update
Nov 18, 2023

Study contacts

William Guyer, PharmD
study director · Corcept Therapeutics, Menlo Park, CA 94025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relacorilant

Start the discussion